Silencing TOP2A has been shown to enhance HCC cells’ sensitivity to regorafenib, suggesting that targeting TOP2A may be a promising therapeutic strategy to alleviate resistance and improve treatment efficacy (25). This evidence concerns the gene TOP2A and hepatocellular carcinoma.